Roth Capital Remains Bullish On BioCryst Pharmaceuticals Ahead Of OPuS-2 Initiation And Rapivab PDUFA
In a research report issued today, Roth Capital analyst Ed Arce reiterated a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a $20 price target, which represents a potential upside of 99% from where the stock is currently trading.
Arce wrote, “Within the next two weeks, BioCryst is expected to initiate OPuS-2, likely the first of two trials sufficient for an NDA submittal of BCX-4161, the only oral prophylactic treatment for the ultra-orphan disease HAE. Within the next week we are anticipating (assuming manufacturing issues are resolved) Rapivab will likely become the first IV drug approved for influenza. We continue to view BioCryst’s HAE portfolio as a pharmacological breakthrough that should ultimately dominate the therapeutic class with peak sales.”
The analyst added, “The approval of Rapivab upon its December 23rd PDUFA date is contingent on full resolution of the issues outlined in the FDA Warning Letter to BioCryst’s contract manufacturing organization (CMO) for Rapivab (peramivir). Nevertheless, even if Rapivab is not approved next week, we remain confident in its approvablity.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Ed Arce has a total average return of 22.3% and a 54.5% success rate. Arce has a 61.1% average return when recommending BCRX, and is ranked #175 out of 3412 analysts.